In-house roundup: Poll shows UPC attractive without UK; generics support European SPC system; antibody case law better in US than Europe

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

In-house roundup: Poll shows UPC attractive without UK; generics support European SPC system; antibody case law better in US than Europe

Money

Managing IP rounds up the latest news and analysis from patent-focused businesses



Money

Survey: UPC still attractive without UK

In a Patent Strategy poll of more than 50 in-house counsel, 78% of respondents said a harmonised European patent system would still be useful if a post-Brexit UK were unable to participate. Read more... 


Poll: SPC system wanted by most generics

In part two of Patent Strategy’s survey, almost all in-house respondents backed a European SPC system, but were less unified on the SPC Regulation’s reliability for new technologies or third-party MAs. Read more... 


Antibody case law clearer in the US than Europe

Pharma innovators say clearer standards on how monoclonal antibody patent applications are reviewed at the USPTO and US national courts have made it easier to file patents there than at the EPO. Read more... 




more from across site and SHARED ros bottom lb

More from across our site

The tie-up could result in the firm’s German and France-based teams, which both have strong UPC expertise, becoming independent
News of a slowdown in the UK’s clean energy IP landscape and an EPO report on unitary patent uptake were also among the top talking points
Price hikes at ‘big law’ firms are pushing some clients toward boutiques that offer predictable fees, specialised expertise, and a model built around prioritising IP
The Australian side, in particular, can benefit by capitalising on its independent status to bring in more work from Western countries while still working with its former Chinese partner
Koen Bijvank of Brinkhof and Johannes Heselberger of Bardehle Pagenberg discuss the Amgen v Sanofi case and why it will be cited frequently
View the official winners of the 2025 Social Impact EMEA Awards
King & Wood Mallesons will break into two entities, 14 years after a merger between a Chinese and an Australian firm created the combined outfit
Teams from Shakespeare Martineau and DWF will take centre stage in a dispute concerning the registrability of dairy terminology in plant-based products
Senem Kayahan, attorney and founder at PatentSe, discusses how she divides prosecution tasks, and reveals the importance of empathetic client advice
The association’s Australian group has filed a formal complaint against the choice of venue, citing Dubai as an unsafe environment for the LGBTQIA+ community
Gift this article